EP-1395: Long term results and technology impact of 48 Gy SABR for inoperable peripheral stage I lung cancer

E. Dubaere, M. Goffaux, B. Bihin, C. Gheldof, A.S. Demoulin, A. Bolly, F. Bustin, F. Duplaquet, P.E. Baugnee, M. Gustin, V. Hers, F. Maisin, E. Marchand, S. Ocak, O. Vancutsem, E. Van Neck, M. Wanet, L. Zaharia, G. Vandermoten, A. Van EschV. Remouchamps

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)S761-S762
JournalRadiotherapy and Oncology
Volume127
DOIs
Publication statusPublished - 18 Jun 2018

Cite this

Dubaere, E. ; Goffaux, M. ; Bihin, B. ; Gheldof, C. ; Demoulin, A.S. ; Bolly, A. ; Bustin, F. ; Duplaquet, F. ; Baugnee, P.E. ; Gustin, M. ; Hers, V. ; Maisin, F. ; Marchand, E. ; Ocak, S. ; Vancutsem, O. ; Van Neck, E. ; Wanet, M. ; Zaharia, L. ; Vandermoten, G. ; Van Esch, A. ; Remouchamps, V. / EP-1395: Long term results and technology impact of 48 Gy SABR for inoperable peripheral stage I lung cancer. In: Radiotherapy and Oncology. 2018 ; Vol. 127. pp. S761-S762.
@article{dc9979dc527c4100b0f0bcf8b273749f,
title = "EP-1395: Long term results and technology impact of 48 Gy SABR for inoperable peripheral stage I lung cancer",
author = "E. Dubaere and M. Goffaux and B. Bihin and C. Gheldof and A.S. Demoulin and A. Bolly and F. Bustin and F. Duplaquet and P.E. Baugnee and M. Gustin and V. Hers and F. Maisin and E. Marchand and S. Ocak and O. Vancutsem and {Van Neck}, E. and M. Wanet and L. Zaharia and G. Vandermoten and {Van Esch}, A. and V. Remouchamps",
year = "2018",
month = "6",
day = "18",
doi = "10.1016/s0167-8140(18)31704-3",
language = "English",
volume = "127",
pages = "S761--S762",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier",

}

Dubaere, E, Goffaux, M, Bihin, B, Gheldof, C, Demoulin, AS, Bolly, A, Bustin, F, Duplaquet, F, Baugnee, PE, Gustin, M, Hers, V, Maisin, F, Marchand, E, Ocak, S, Vancutsem, O, Van Neck, E, Wanet, M, Zaharia, L, Vandermoten, G, Van Esch, A & Remouchamps, V 2018, 'EP-1395: Long term results and technology impact of 48 Gy SABR for inoperable peripheral stage I lung cancer', Radiotherapy and Oncology, vol. 127, pp. S761-S762. https://doi.org/10.1016/s0167-8140(18)31704-3

EP-1395: Long term results and technology impact of 48 Gy SABR for inoperable peripheral stage I lung cancer. / Dubaere, E.; Goffaux, M.; Bihin, B.; Gheldof, C.; Demoulin, A.S.; Bolly, A.; Bustin, F.; Duplaquet, F.; Baugnee, P.E.; Gustin, M.; Hers, V.; Maisin, F.; Marchand, E.; Ocak, S.; Vancutsem, O.; Van Neck, E.; Wanet, M.; Zaharia, L.; Vandermoten, G.; Van Esch, A.; Remouchamps, V.

In: Radiotherapy and Oncology, Vol. 127, 18.06.2018, p. S761-S762.

Research output: Contribution to journalArticle

TY - JOUR

T1 - EP-1395: Long term results and technology impact of 48 Gy SABR for inoperable peripheral stage I lung cancer

AU - Dubaere, E.

AU - Goffaux, M.

AU - Bihin, B.

AU - Gheldof, C.

AU - Demoulin, A.S.

AU - Bolly, A.

AU - Bustin, F.

AU - Duplaquet, F.

AU - Baugnee, P.E.

AU - Gustin, M.

AU - Hers, V.

AU - Maisin, F.

AU - Marchand, E.

AU - Ocak, S.

AU - Vancutsem, O.

AU - Van Neck, E.

AU - Wanet, M.

AU - Zaharia, L.

AU - Vandermoten, G.

AU - Van Esch, A.

AU - Remouchamps, V.

PY - 2018/6/18

Y1 - 2018/6/18

UR - http://www.mendeley.com/research/ep1395-long-term-results-technology-impact-48-gy-sabr-inoperable-peripheral-stage-i-lung-cancer

U2 - 10.1016/s0167-8140(18)31704-3

DO - 10.1016/s0167-8140(18)31704-3

M3 - Article

VL - 127

SP - S761-S762

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

ER -